GLP-1 Medications and Testosterone: What Happens to Hormones on Ozempic

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and others — have transformed the treatment of obesity. Clinical trials show weight losses of 15–20% of body weight, outcomes previously achievable only with bariatric surgery. [^wilding2021]

For men taking these medications, a key question follows: what happens to testosterone?

The short answer is that weight loss from any cause reliably raises testosterone in overweight and obese men — and GLP-1 medications produce significant weight loss. But the full picture involves timing, muscle mass considerations, and the distinction between weight loss itself and any direct hormonal effects of the drugs.

Why Weight Loss Raises Testosterone

The mechanism is aromatase. Adipose (fat) tissue expresses aromatase, the enzyme that converts testosterone to estradiol. More fat = more aromatase = more testosterone converted to estrogen. [^lapauw2016]

This conversion has cascading effects:

1. Testosterone is directly depleted through conversion to estradiol
2. Elevated estradiol suppresses GnRH and LH via negative feedback
3. Reduced LH means reduced testicular testosterone synthesis
4. The testosterone-to-estrogen ratio shifts unfavorably

When a man loses significant fat mass, aromatase activity decreases, testosterone-to-estrogen conversion falls, HPG axis suppression is reduced, and total and free testosterone rise.

This mechanism is well-established in the literature. Large studies of men undergoing bariatric surgery show testosterone increases of 30–50% within the first year — with ongoing improvements over 2–3 years of sustained weight loss. [^grossmann2019]

What the GLP-1 Data Shows

The evidence specifically for GLP-1 medications and testosterone is early but consistent with the broader weight-loss-testosterone relationship.

A study by Jensterle et al. in obese men with type 2 diabetes found that liraglutide treatment over 12 weeks produced both significant weight loss and significant testosterone increases. [^nissen2021] The testosterone improvement correlated with the degree of weight loss rather than with time on medication, suggesting the hormonal change was driven by fat loss rather than any direct drug effect.

Larger trials of semaglutide have not yet published primary testosterone outcome data, but secondary analyses consistently show improvements in hormones related to the metabolic syndrome — including testosterone — proportional to weight reduction.

Whether GLP-1 medications have direct gonadotropic effects independent of weight loss is under active investigation. GLP-1 receptors are present in the hypothalamus and pituitary, raising the theoretical possibility of direct HPG axis effects. Current evidence does not support meaningful direct hormonal effects at therapeutic doses, but this question is not definitively settled.

The Muscle Mass Consideration

GLP-1 medications cause weight loss that is not entirely from fat. Depending on protocol, 25–40% of weight lost on GLP-1 medications may be lean mass (muscle), not fat. [^cohen2023] This is higher than the lean mass loss seen with bariatric surgery (approximately 20%) and raises an important concern.

Muscle mass loss during weight loss has several hormonal and functional implications:

• Testosterone relationship: Testosterone is anabolic — it supports muscle maintenance. Rapid weight loss that includes muscle loss can paradoxically reduce testosterone despite losing fat, because the anabolic signal that muscle mass provides is reduced.
• Metabolic rate: Muscle mass is metabolically active. Losing muscle reduces resting metabolic rate, increasing the likelihood of weight regain.
• Functional strength: Physical strength and independence depend on muscle mass, particularly relevant in older men.

Resistance training during GLP-1 therapy substantially reduces lean mass loss. Studies show that men who engage in consistent resistance training while on GLP-1 medications lose proportionally more fat and less muscle than those who do not exercise. [^bhasin2006]

Testosterone and GLP-1: Timeline

Based on available data and the mechanism:

The degree of testosterone increase depends heavily on starting testosterone level and starting body fat percentage. Men with the lowest baseline testosterone and highest body fat show the largest proportional gains. [^jayasena2019]

Men who begin GLP-1 medications with borderline-low testosterone (250–350 ng/dL) may find that sustained weight loss normalizes their testosterone without requiring testosterone therapy — though this should be confirmed by retesting after significant weight loss (at least 10% body weight).

Does GLP-1 Treatment Replace Testosterone Therapy?

For men currently on testosterone replacement therapy (TRT) who begin GLP-1 treatment and lose significant weight, the question of whether TRT remains necessary should be revisited after substantial weight loss. In some men, weight loss will raise endogenous testosterone to levels that make TRT unnecessary. This requires formal retesting under the guidance of the prescribing physician — not unilateral stopping of TRT.

For men considering both GLP-1 medication and TRT, the sequencing matters. Beginning with GLP-1 and assessing hormone levels after significant weight loss before initiating TRT avoids potentially unnecessary testosterone supplementation.

Libido and Sexual Function on GLP-1 Medications

Some men report improved libido and sexual function on GLP-1 medications — consistent with the testosterone and metabolic improvements described above. Weight loss itself improves self-image, physical energy, and confidence, all of which contribute to sexual function through psychological as well as hormonal mechanisms.

A small proportion of men report reduced libido on GLP-1 medications, particularly early in treatment when nausea is most prominent. Nausea-driven caloric reduction and general malaise temporarily suppress libido; this typically resolves as gastrointestinal side effects diminish over the first 4–8 weeks.

Practical Guidance for Men on GLP-1 Medications

1. Test testosterone before starting: Baseline measurement allows meaningful comparison after weight loss
2. Add resistance training: Critical for preserving lean mass and maximizing hormonal benefit
3. Ensure adequate protein: 1.6–2.0 g/kg/day of protein supports muscle preservation during weight loss
4. Retest testosterone after 10–15% weight loss: May show meaningful improvement; guides need for additional hormonal intervention
5. Sleep and stress management: These continue to drive hormonal outcomes independent of weight
6. If on TRT: Discuss reassessment timeline with prescribing physician after sustained weight loss

Bottom Line

GLP-1 medications raise testosterone in overweight and obese men primarily through weight loss-driven reduction in aromatase activity — the same mechanism by which any substantial weight loss improves testosterone. The effect is real and clinically meaningful. The muscle mass loss associated with GLP-1 medications can partially offset hormonal benefits and requires active mitigation through resistance training and adequate protein. Men using these medications should incorporate hormonal monitoring and structured exercise to maximize the benefits these drugs create.